The new facility will employ 40-50 researchers.
Switzerland's Ferring Pharmaceuticals AG has dedicated its Israeli R&D center in Beer Tuvia, built at an investment of $2.7 million. The development and regulatory staff of Biotechnology General Ltd., which Ferring acquired in 2005, moved to the new facility after the closing down of the old one in Ness Ziona.
The new R&D center will employ 40-50 researchers who will focus on analytical development of biopharmaceuticals, especially recombinants. The center will have laboratories and clinical trial facilities to support products based on microbiological research and cell cultures. The R&D center is a new wing to an existing production facility, enabling collaboration between the company's research and production staff.
Ferring develops and markets endocrinology, gastroenterology, gynecology, fertility, urology, and other products. The company operates in more than 40 countries worldwide. It established a sales and marketing office in Israel in 2000.
Published by Globes [online], Israel business news - www.globes-online.com - on December 12, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007